Protein tyrosine sulphation is a post-translational modification (PTM) best known for regulating 1 8 extracellular protein-protein interactions. Tyrosine sulphation is catalysed by two Golgi-resident 1 9 enzymes termed Tyrosyl Protein Sulpho Transferases (TPSTs) 1 and 2, which transfer sulphate from 2 0 the co-factor PAPS (3'-phosphoadenosine 5'-phosphosulphate) to a context-dependent tyrosine in a 2 1 protein substrate. A lack of quantitative tyrosine sulphation assays has hampered the development of 2 2 chemical biology approaches for the identification of small molecule inhibitors of tyrosine sulphation.
Analysis of TPST-based catalysis using small molecules remains in its infancy, and is currently 1 0 7 hampered by a lack of rapid, flexible and reliable assays with which to screen for suitable inhibitors. Thermal and enzymatic screening assays can generate complementary information to help evaluate inhibitors, we developed a novel enzyme assay for kinetic analysis of peptide tyrosine sulphation. The 2 8 2 basic requirement of this assay was that it should report the enzymatic incorporation of sulphate onto 2 8 3 a tyrosine residue of a synthetic peptide substrate with a high signal-to-noise ratio and be rapid, 1 1 repeatable and relatively high-throughput. Current protocols to monitor tyrosine sulphation generally 2 8 5 involve 35 S-based enzyme regeneration or intrinsic fluorescence assays, which are often unsuitable for 2 8 6 kinetic or high-throughput analysis using different peptide substrates, and are prone to artefacts if 2 8 7 compounds or co-factors that interfere with fluorescence detection are employed. However, as 2 8 8 established below, our novel assay permits rapid real-time detection of non-radioactive sulphate 2 8 9 incorporation into synthetic peptides. To evaluate context-specific sulphation kinetics for TPST1 and 2, we synthesised a panel of peptides 2 9 2 possessing tyrosine-containing sequences found in human proteins previously reported to be sulphated 2 9 3 on tyrosine [2], and developed an assay to quantify peptide sulphation. The assay comprises a putative 2 9 4 substrate peptide (containing a tyrosine in an acid context and culminating in an amide group), TPST1 2 9 5 or TPST2 and the PAPS co-factor ( Figure 2A ). To facilitate the facile detection of both sulphated and 2 9 6 non-sulphated substrates in the same assay using a microfluidic platform, we appended an N-terminal 2 9 7 fluorophore (5-FAM) to the peptide. Since tyrosylsulphate (singly charged under the assay conditions) 2 9 8 and tyrosylphosphate (doubly charged) are chemically similar, and can potentially induce charge-2 9 9 based differences in peptide mobility when covalently attached to tyrosine, we reasoned that this 3 0 0 assay would be able to detect sulphation in a similar way to that previously established for tyrosine unmodified substrate (S). Different ratios of product to substrate were detected when TPST1 or 3 0 5 TPST2 were included in the assay, but no product was detected with buffer and PAPS alone, suggesting that the new product was a tyrosine-sulphated peptide ( Figure 2B ).
0 7
We next compared the ability of TPST1 and TPST2 to modify the CC4 peptide (termed hereafter 3 0 8 CC4-tide) in a kinetic assay, monitoring the real-time appearance of the sulphated peptide by 3 0 9 detecting the increase in product peak height in a duplicate assay format. As shown in Figure 2C ,
TPST1 was much more efficient at modifying CC4-tide, inducing near-stoichiometric modification 3 1 1 after one hour. The rate of sulphation by TPST1, but not TPST2, was responsive to divalent cations, 3 1 2 and could be increased 6-10 fold by including Mg 2+ ions or Mn 2+ ions in the buffer (Supplementary Figure 1A , B), consistent with previous studies [18, 28, 40] . In contrast, over the same time period and at the same concentration in the assay, purified TPST2 only sulphated CC4-tide to a 3 1 6 stoichiometry of ~20%. We next assessed whether TPST1 or TPST2 sulphated a fluorescent 14-mer 3 1 7 peptide derived from recombinant human FGF7, which contains a single known site of tyrosine 3 1 8 sulphation corresponding to Tyr27 in the mature growth factor [57] . Using this new assay, we were unable to detect FGF7-tide sulphation by TPST2, although TPST1 induced ~70% peptide sulphation 3 2 0 over the assay time-course ( Figure 2D ). Interestingly, CCR8-tide, which was derived from the human 3 2 1 CCR8 sequence, was even more rapidly sulphated by TPST1 than FGF7-tide, although it was not 3 2 2 modified noticeably by TPST2 ( Figure 2E ). In marked contrast, a distinct fluorescent 14-mer 3 2 3 sequence derived from human PSGL1 was rapidly, and stoichiometrically sulphated by TPST1 and 3 2 4 TPST2 ( Figure 2F ), confirming these enzymes possess overlapping, as well as distinct, substrate 3 2 5 specificities in vitro. As a test of the suitability of our assay to derive a reported kinetic parameter, we 3 2 6 employed an appropriate concentration of TPST1 and 2 so that the degree of peptide sulphation was previous literature reports of 2-5 μM for TPST1 [18, 25] To investigate TPST site specificity, we confirmed that the single Tyr residue in CC4 represents the was substituted for a chemically analogous, but non-sulphatable, Phe residue. As shown in Figure 3A co-factor specificity in the assay, we evaluated sulphation and phosphorylation of the same CC4-tide 3 3 8 substrate using either TPST1 or the tyrosine kinase Ephrin A3. Importantly, Ephrin A3 generated a Figure 3C ). The electrophoretic mobility of sulphated (TPST1-generated) or phosphorylated (EphA3-3 4 2 generated) CC4 peptides relative to the non-modified peptide was very similar in our microfluidic optimised for EphA3 phosphorylation was not modified by TPST1 or TPST2, presumably because it lacked an acidic residue at the -1 position relative to Tyr, although this did not prevent phosphorylation by EphA3 kinase in the presence of Mg-ATP ( Figure 3D ). approach to study this covalent modification in vitro. In order to unambiguously confirm sulphation antibody that specifically recognises sulphated tyrosine in intact proteins. Initially, we generated a 3 5 5 recombinant protein consisting of Glutathione S-tranferase (GST) fused to the CC4-tide sequence 3 5 6 (EDFEDYEFDG) that was developed for TPST1 and TPST2 mobility-based enzyme assays (Figures 3 5 7 2 and 3). As detailed in Figure 4A , this GST fusion protein became sulphated on tyrosine only after 3 5 8 incubation with TPSTs, and this modification required PAPS in the assay. Consistently, GST was not 3 5 9
detectably sulphated under any condition, confirming that the CC4-tide sequence was the target of experiment also demonstrates unequivocally that the modification-specific antibodies can differentiate 3 6 6 between sulphated and phosphorylated forms of the GST-CC4-tide protein. We also confirmed that 3 6 7 full-length recombinant FGF7 was specifically modified by TPST1, but not TPST2 in vitro, consistent 
Analysis of TPST inhibition by biochemical and the protein kinase inhibitor rottlerin
The ability of fluorescent peptide substrates to report TPST1 and TPST2-directed tyrosine sulphation 3 7 2 in a plate-based assay format allowed us to develop an enzyme screen for the analysis and discovery activity towards multiple substrates, we focused our biochemical screening studies on TPST1. As 3 7 5 detailed in Figure 5A , the TPST ligands PAP, CoA, dephospho-CoA and ATP were all able to inhibit the broad-spectrum kinase inhibitor rottlerin, which was originally described as a 'specific' cellular 3 8 9 PKC inhibitor [60], but later revealed to be a non-specific protein kinase inhibitor [61], inhibited 3 9 0 PAPS-dependent TPST1 and TPST2 with single-digit micromolar IC 50 values ( Figure 6A ). We also rottlerin binding also induced a positive TPST1 and TPST2 thermal shift ( Figure 6B ), although the 3 9 5 degree of stabilisation relative to ATP was lower than predicted, given the potent inhibitory effect of 3 9 6 rottlerin on TPST1 and TPST2 enzyme activity in vitro. Multiple RAF kinase inhibitors target TPST catalytic activity in vitro
The provocative chemical and structural similarities between CoA, PAP, ATP and PAPS ( Figure 1A ), top compound found through this approach was GW406108X, and we noted strong thermal shifts in was measured, some 10-fold higher than that of rottlerin ( Figure 8B ). As shown in Figure 8C In order to model the interaction of hit and control TPST1/2 ligands, including rottlerin, suramin, the 4 3 8 sorafenib-derivative RAF265, and GW305074X with TPST1, we employed molecular docking to PAPS increases in enzyme assays ( Figure 8D ). In contrast, suramin is predicted to form a hydrogen TPSTs catalyze protein sulphation using PAPS as the sulphate group donor, and are thought to In this paper, we report a simple and rapid method for the detection of TPST-catalysed peptide TPST2 preparations for the PAPS co-factor was found to be almost identical to that previously 4 7 9
reported, and we confirmed that TPST1 and TPST2 were folded and could bind to a variety of We confirmed by DSF that TPST ligands act as competitive active-site inhibitors of peptide 4 9 1 sulphation, creating a new impetus to develop novel screening approaches to discover TPST peptide sulphation assay detects modification in real-time using a simple mobility shift assay, which is course of our studies, we established a high reproducibility for this assay, and exploited it to probe 5 0 3 substrate specificity and discover new enzyme inhibitors. We also generated a substrate lacking a key and FGF7 substrates for TPST1, which were not substrates for TPST2, and dual substrates with 5 0 7 differential (CC4-tide) or very similar (PSGL1) sulphation kinetics for TPST1 and TPST2. Based on 5 0 8 our initial analyses, we found that TPST2 only sulphated tyrosine-containing peptide substrates with 5 0 9 an acidic residue in both the +1 and -1 position, whereas TPST1 dependent tyrosine sulphation only 5 1 0 required a negative charge to be present in the -1 site (Figure 2) . Future work will employ a much 5 1 1 larger selection of peptide substrates to evaluate this preference further, with a goal of defining 5 1 2 TPST1 and TPST2 substrate specificity in vitro that can be exploited to help examine the 5 1 3 sulphoproteomic datasets emerging from cell-based studies. Our finding that TPST1 was inhibited at sub-micromolar concentrations by the anti-angiogenic 5 1 6 compound suramin, which has been used clinically to treat River Blindness and African intriguing, and consistent with a very recent report demonstrating inhibitory activity towards TPSTs [40]. By screening a panel of kinase inhibitors, we found that rottlerin (also known as mallotoxin) is 5 2 0 also a low micromolar inhibitor of TPST1 and TPST2 in vitro. Rottlerin was originally identified as kinases in vitro [61] . Interestingly, we discovered that all three of these compounds also have heightened the possibility that other kinase inhibitors might also be serendipitous TPST inhibitors.
2 9
To evaluate this hypothesis, we identified a number of TPST1 ligands in PKIS. Intriguingly, 4 of the next confirmed that distinct RAF inhibitors also possess inhibitory properties towards TPST1.
3 5
Interestingly, well-validated clinical RAF inhibitors, including RAF265 (IC 50 6.5 μM), vemurafenib 5 3 6 (IC 50 ~40 μM) and the much higher micromolar TPST inhibitor sorafenib (which contains the same 2- arylaminobenzimidazole chemical scaffold found in RAF265, Supplementary Figure 7) , were also 5 3 8 TPST1 inhibitors in vitro. These findings demonstrate that many compounds designed as RAF 5 3 9
inhibitors also have the ability to inhibit TPST1, providing a new impetus to exploit the huge amount oxindole-based c-RAF inhibitors was some 10-fold higher than that for TPST1, and we confirmed that In order to stimulate progress in implementing chemical biology in the sulphotransferase field, careful 5 5 2 structure-based comparison between HS2ST, TPST1/2 and RAF kinases inhibition, and analysis of a 5 5 3 wide variety of compound chemotypes, will be required. Our docking studies with TPST1 suggest 5 5 4 similar binding modes for both rottlerin and the potent oxindole TPST1 inhibitor GW305074X binding sites. It will be intriguing to confirm these binding modes through structural analysis and 5 5 7 guided enzyme mutagenesis, and to identify drug-binding site residues in sulphotransferases that 5 5 8 dictate inhibition. This information can then be used for careful compound analysis and the generation 5 5 9 of drug-resistant alleles for cellular analysis, using concepts developed for compound target validation 0 this context it is useful to recall the rapid development of the kinase inhibitor field as an exemplar.
7 1
Initial scepticism about the feasibility (or even, the need) to generate specific inhibitors of protein 5 7 2 kinases has been largely overcome [87], partly through innovative synthetic approaches, but also by a Finally, inhibitor-based interrogation of TPST-dependent tyrosine sulphation could be employed research by increasing our ability to chemically control and modulate tyrosine sulphation and even [87], we suggest that a new opportunity might also soon exist to integrate the analysis of TPST with inhibitors of tyrosine-specific protein kinases. The Journal of biological chemistry, 1984. 
